Oral Contraceptives Not Linked to Ovarian, Breast Cancer in High-Risk Women

This article originally appeared here.
Share this content:
Pill Effects on Breast, Ovarian CA Same in High-Risk Women
Pill Effects on Breast, Ovarian CA Same in High-Risk Women

(HealthDay News) -- Among women who are BRCA1/2 mutation carriers, the associations between ever use of oral contraceptives (OCs) and ovarian and breast cancers are similar to those observed in the general population, according to research published online Oct. 21 in the Journal of Clinical Oncology.

Patricia G. Moorman, Ph.D., of Duke University in Durham, N.C., and colleagues performed a systematic review of the literature and meta-analysis to estimate the risks of breast cancer and ovarian cancer associated with use of OCs in women at increased risk.

The researchers note that meta-analysis showed a significant inverse association between OC use and ovarian cancer (odds ratio [OR], 0.58; 95% confidence interval [CI], 0.46 to 0.73) and a non-significant association between OC use and breast cancer (OR, 1.21; 95% CI, 0.93 to 1.58) for BRCA1 and BRCA2 mutation carriers combined. Similar patterns were observed when mutation carriers were analyzed separately.

"Our analyses suggest that associations between ever use of OCs and ovarian and breast cancer among women who are BRCA1 or BRCA2 mutation carriers are similar to those reported for the general population," the authors write.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs